DX-88, an internally discovered, recombinant, plasma kallikrein inhibitor, is in clinical trials for the treatment of acute attacks of hereditary angioedema (HAE), a rare genetic disease characterized by episodes of acute swelling and inflammation.
Statistically significant results were achieved for both the primary and secondary endpoints in the trial. Furthermore, the overall safety results showed that DX-88 continues to be well tolerated and there were no drug-related serious adverse events.
The primary objective of the phase III trial was to determine the efficacy and safety of the fixed 30mg subcutaneous dose of DX-88 for patients suffering from moderate to severe acute HAE attacks.